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A B S T R A C T
Background: CPC634 is docetaxel entrapped in core-cross linked polymeric micelles. In preclinical studies,
CPC634 demonstrated enhanced pharmacokinetics and improved therapeutic index. This phase I dose escalation
study is the first-in-human study with CPC634.
Methods: adult patients with advanced solid tumours received CPC634 intravenously either 3-weekly (Q3W)
(part 1, dose range 15–100 mg/m2), 2-weekly (Q2W) (part 2, 45 mg/m2) or Q3W with dexamethasone pre-
medication (part 3, 60 mg/m2).
Results: thirty-three patients were enrolled. Skin toxicity was dose limiting (DLT) at ≥60 mg/m2 in part 1 and
at 45 mg/m2 in part 2 and was the most common CPC634 related grade ≥ 3 adverse event (24%). With dex-
amethasone premedication no DLTs were observed at 60 mg/m2 Q3W. CPC634 exhibited a dose-proportional
pharmacokinetic profile. At 60 mg/m2, the plasma area under the curve was 4067.5 ± 2974.0 ng/h/mL and the
peak plasma level 217.3 ± 91.9 ng/mL with a half-life of 39.7 ± 9.4 h for released docetaxel.
Conclusion: CPC634 could be administered safely upon pretreatment with dexamethasone. Cumulative skin
toxicity was the main DLT. The recommended phase 2 dose was determined at 60 mg/m2 Q3W with dex-
amethasone premedication.
1. Background
Docetaxel is an antimicrotubule agent registered for multiple in-
dications and is usually administered 3-weekly (Q3W) at doses ranging
from 60 to 100 mg/m2 [1–3]. Important limitations of docetaxel are
acute hypersensitivity reactions, neutropenia, neuropathy, fatigue,
nausea, vomiting and nail toxicity [2–4].
Nanotechnology is a novel drug delivery method to improve the
pharmacokinetic behaviour of cytotoxic drugs through the so-called
enhanced permeability and retention effect [5]. This enhanced per-
meability effect is a unique phenomenon in solid tumours and is related
to high vascular density and large endothelium fenestrations enabling
selective extravasation and accumulation of nanomedicines within the
tumour interstitium. As a result, intratumoural drug concentrations can
be several-fold higher than those in normal tissues [6]. Several nano-
particles have been developed that are physical assemblies like lipo-
somes and traditional micelles. These physical assemblies are often
prone to premature drug release and/or rapid disintegration upon entry
into the circulation [7]. This poor pharmacokinetic profile is pre-
sumably the reason why most of the current nanoformulations in clin-
ical trials show a comparable toxicity profile to the native drug and only
a few show improved efficacy [5,8,9]. CPC634 is a novel nanomedicine
consisting of docetaxel covalently entrapped in a stabilized, 65 nm
sized core-cross linked polymeric micelles (CCL-PMs) [10,11]. CCL-PMs
are composed of poly (ethylene glycol)-b-poly[N-(2-hydroxypropyl)
methacrylamidelactate] copolymers, partially derivatised with metha-
crylate moieties to enable crosslinking after micelle formation. Doc-
etaxel is covalently crosslinked to CCL-PMs via a hydrolysable ester
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T
linker (see supplementary file 1 for structure formula) to enable in-
itially good stability upon administration, a prolonged circulation and
thereby increased intratumoural drug accumulation as well as a con-
trolled drug release from the CCL-PMs [12]. In preclinical studies,
CPC634 demonstrated this prolonged systemic circulation and en-
hanced tumour uptake resulting in improved antitumour activity [11].
In MDA-MB-231 breast cancer xenograft mice, CPC634 single-dose
administration resulted in complete tumour free survival at a dose of
125 mg/kg which exceeded the 98 mg/kg maximum tolerated dose
(MTD) for generic docetaxel. At a dose level of 60 mg/kg, conventional
docetaxel showed less efficacy and a significantly worse toxicity profile
[11]. Additionally, in a 5-day repeated dose toxicity study in healthy
rats, CPC634 toxicities were substantially reduced compared to con-
ventional docetaxel, despite a 45% higher dose. In addition, haemato-
logical toxicities were significantly lower in rats that received CPC634
[11]. Recently, CPC634 demonstrated an improved circulation and
target site accumulation in a clinical head-to-head comparison with
conventional docetaxel [13]. This first-in-human phase 1 dose escala-
tion study evaluated the safety and determined the recommended phase
2 dose (RP2D), pharmacokinetic profile, and preliminary antitumour
activity of CPC634 in patients with various types of solid tumours.
2. Methods
2.1. Study design and dose escalation
This was a three-part, open label, dose escalation study in patients
with solid tumours conducted at two sites in the Netherlands and one
site in Belgium (Clinicaltrials.gov number NCT02442531). Dose esca-
lation followed a standard 3 + 3 design. According to a 3 + 3 design at
least 3 patients are treated at each dose level, by applying the following
rules; 1. dose escalation to the next dose level if no dose limiting
toxicity (DLT) occurs, 2. if 1 out of 3 patients experiences a DLT, treat 3
additional patients at this dose level, 3. stop dose escalation if ≥2 out of
3 or ≥ 2 out of 6 patients experience a DLT [14]. In part 1 and in part 2
CPC634 was administered without premedication. CPC634 was ad-
ministered every three weeks (Q3W) in part 1. In part 2, CPC634 was
administered once every two weeks (Q2W) to explore if the tolerability
of CPC634 could be improved by this dosing schedule. In part 3,
CPC634 was administered once Q3W with oral dexamethasone pre-
medication (8 mg 12, 3 and 1 h before infusion). In part 1 and in part 3,
one treatment cycle was three weeks and comprised of one drug infu-
sion followed by three weeks of rest. In part 2 the duration of one
treatment cycle was set at four weeks and thus comprised of two drug
administrations, each followed by two weeks of rest. A minimum of
three patients were enrolled at each dose level. The starting dose of
15 mg/m2 was calculated as a safe starting dose using one-tenth of the
MTD observed in the single dose acute toxicity study in rats. Pre-
planned dose escalation levels were set at 30, 60, 100, 150, and
210 mg/m2. Part 2 was started after completion of part 1. The starting
dose in part 2 was based on the MTD reached in part 1. The DLT ob-
servation period was one treatment cycle. All dose escalation decisions
were made following completion of the DLT observation period and
after consultation with all the investigators.
Upon completion of treatment cycle 1, patients could receive ad-
ditional treatment cycles, with ongoing safety monitoring. This study
was conducted in accordance with International Conference on
Harmonization Good Clinical Practice guidelines, applicable regula-
tions and guidelines governing clinical study conduct, and ethical
principles that have their origin in the Declaration of Helsinki. The
study protocol was reviewed and approved by the Ethics committee of
all participating centres. All patients provided written informed consent
before participation in the trial.
2.2. Definition of DLT
Safety assessments were done according to Common Terminology
Criteria for Adverse Events (version 4.03). Haematological DLT was
defined as drug-related grade > 3 neutropenia lasting more than
1 week; grade ≥ 3 febrile neutropenia; grade 4 thrombocytopenia, or
grade 3 thrombocytopenia with bleeding requiring platelet transfusion;
grade ≥ 4 anaemia. Non-haematological DLT was defined as any drug
related grade ≥ 3 toxicity with the exception of inadequately treated
nausea, vomiting or diarrhoea. Delayed administration of the study
drug for more than two weeks and any other toxicity which in the view
of the investigator represented a clinically significant hazard to the
patient - even outside the DLT window- also qualified as DLT. The RP2D
was determined by the rate of the DLTs and overall tolerability of re-
peated CPC634 administrations.
2.3. Patients
Eligible patients had a pathologically confirmed diagnosis of an
Table 1
Patient characteristics at baseline.
No (%)
Patients
Screened 49
Enrolled 33
Age (years)
Median 61
Range 48–77
Performance statusa
0 5 (15)
1 28 (85)
Gender
Female 13 (39)
Male 20 (61)
Tumour type
Prostate cancer 7 (21)
Adenocarcinoma of unknown primary origin 3 (9)
Colorectal cancer 3 (9)
Adenoid cystic carcinoma 3 (9)
Small cell lung cancer 2 (6)
Other 15 (45)
Previous systemic treatment
Yes 31 (94)
No 2 (6)
> 2 lines of chemotherapy
Yes
15 (46)
No 18 (55)
Previous treatment with taxanes
Yes 12 (36)
No 21 (64)
a Eastern Cooperative Oncology performance status.
Fig. 1. Appearance of cumulative skin toxicity; presence of maculopapular rash
with erythema on the lower limb and foot in a patient in the 70 mg/m2 cohort.
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advanced solid tumour with no standard therapy options, with mea-
surable disease according to Response Evaluation Criteria in Solid
Tumours (RECIST) version 1.1. Eligible patients were ≥ 18 years of
age, had an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1 and had adequate haematological, liver and renal
function (extended inclusion and exclusion criteria are described in
supplementary file 2A).
2.4. Treatment
CPC634 was provided by Cristal Therapeutics (Maastricht, The
Netherlands). Preparation of CPC634 before administration included
thawing for 16–24 h in a 2–8 °C refrigerator. On the day of adminis-
tration CPC634 vials were placed at room temperature (18–25 °C) for
1.0 h to reach ambient temperature before administration. CPC634 was
administered intravenously over 60 min.
2.5. Pharmacokinetic assessments
In part 1, plasma samples for docetaxel measurement were collected
at the following time points during treatment cycles 1 and 2: 0, 5, 15,
30 min, 1, 1.5, 2, 4, 6, 24 h, 2–4 and 7 days after drug infusion. In part
2, pre-dose plasma samples were taken during treatment cycles 1 to 3
and one sample after administration of CPC634 in cycle 1. In part 3,
only pre-dose plasma samples were taken during treatment cycles 1 to 4
to demonstrate the absence of any drug accumulation upon repeated
administration. The bioanalytical validation and sample measurement
was conducted by BioClin Research Laboratories Ltd. (Athlone,
Ireland). Total and released docetaxel human plasma samples were
analysed by high-pressure liquid chromatography with tandem mass
spectrometric detection using turbo ion spray (supplementary file 2B).
The lower limit of quantification was 100 ng/mL for total and 1 ng/mL
for released docetaxel. Determination of the relevant pharmacokinetic
parameters included the maximum plasma concentration (Cmax) and its
corresponding time (Tmax), area under the curve (AUC) from time of
dosing extrapolated to infinity (AUCinf), the elimination half-life (T½),
total plasma clearance (CL/m2) and the volume of distribution (Vd L/
m2) (supplementary file 2B).
2.6. Antitumour activity
Antitumour activity was assessed by the investigators using RECIST
version 1.1. In part 1 and in part 3, response evaluation was performed
at the end of treatment cycles 2, 4, and 6 and subsequently after every
3 cycles; and at end of treatment. In part 2, response evaluation was
performed every eight weeks and at the end of study participation. The
duration of response was defined as the number of days from the date of
first response to the earliest documentation of radiographic progressive
disease (PD) or death of all causes.
2.7. Statistical analyses
Patients who received at least one dose of CPC634 were included in
the safety assessment. Descriptive statistics were used for patient
characteristics, pharmacokinetic parameters of CPC634, safety and ef-
ficacy data. All the pharmacokinetic descriptive statistics were calcu-
lated using Phoenix® WinNonlin® Version 7 (Certara USA, Inc.,
Princeton, NJ, USA). The data cut-off for analysis of safety and anti-
tumour activity was July 23, 2018. The non-parametric Mann Whitney
test was used to compare the pharmacokinetic profile of patients ex-
periencing DLT with patients without DLT.
3. Results
3.1. Patient characteristics
Thirty-three patients (part 1; n = 24, part 2; n = 3, part 3; n = 6)
with various solid tumours were included between July 2015 and June
2018 (Table 1).
3.2. Dose escalation and DLTs
In part 1, dose escalation could be pursued from 15 up to 100 mg/
m2. No DLTs were observed at 15, 30 and 60 mg/m2 during treatment
cycle 1. Therefore, CPC634 dose was escalated to 100 mg/m2. At
100 mg/m2, one patient developed neutropenia grade 4 lasting<7
days. Treatment cycle 2 for this patient was therefore reduced to
80 mg/m2. During treatment cycle 2 the patient was admitted to hos-
pital due to bullous skin rash grade 3 and a coinciding pneumonia grade
4. Both events were considered potentially related to CPC634. The
second patient at 100 mg/m2 developed bullous skin rash grade 2 and
neutropenia grade 3 lasting<7 days in cycle 1. Treatment cycles 2 and
3 were therefore reduced to 80 mg/m2. The third patient at 100 mg/m2
developed maculopapular skin rash grade 2 during treatment cycle 1,
and received cycle 2 and 3 at 80 mg/m2. During treatment cycle 3, this
patient developed palmar-plantar erythrodysesthesia syndrome (PPE)
Table 2
Overview of all the dose levels with the number of patients experiencing dose limiting toxicities (DLTs).
CPC634 dose
(mg/m2)
DLT ratio DLT Received > 2 cycles Median number of
received cycles
AE leading to dose
reduction
CPC634 related
grade ≥ 3 AE
Off-study due to
CPC634 related
toxicity
Part 1 (without dexamethasone)
15 0/3 – 2 6 (2−23) 0 1 0
30 0/3 – 1 2 (2–3) 0 0 0
60 0/3 – 1 3 (1–4) 0 0 0
100 3/3 Skin rash grade 2 and grade 3,
PPE grade 3
2 3 (2–3) 3 7 3
80 2/3 Fatigue grade 3; skin rash grade
3
1 2 (2–3) 1 1 2
70 1/6 Skin rash grade 3 2 2 (1–4) 2 5 1
60 2/3 Colitis grade 3;
skin rash grade 3
2 3 (2–7) 2 7 1
Part 2 (without dexamethasone)
45 2⁎/3 Hypomagnesemia grade 3;
skin rash grade 3; PPE grade 3
0 3 (3–4) 0 3 2
Part 3 (with dexamethasone premedication)
60 0/6 – 5 5.5 (2–9) 0 3 2
Abbreviations; AE, adverse event; PPE, palmar-plantar erythrodysaesthesia; ⁎ one patient in part 2 experienced 2 DLTs; hypomagnesemia grade 3 and rash grade 3.
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grade 3.
Following the observation of possible cumulative (and potentially
dose-limiting) skin toxicity beyond treatment cycle one, the DLT ob-
servation period, with particular emphasis on skin toxicity, was ex-
tended beyond treatment cycle 1 to better assess the clinical toxicity.
Next, a lower dose level of 80 mg/m2 was explored in 3 patients. One
patient experienced intermittent fatigue grade 3 during treatment cycle
1. Treatment cycle 2 was given at 80 mg/m2. The second patient re-
ceived CPC634 at a dose of 80 mg/m2 during treatment cycle 1 and 2.
During treatment cycle 2 the patient developed skin rash grade 2 which
impeded further administrations of CPC634. The skin toxicity was
considered as DLT. The third patient received two treatment cycles at
80 mg/m2. Due to skin PPE grade 2 during treatment cycle 2, the third
cycle was given at a reduced dose of 60 mg/m2. Subsequently, a lower
dose level of 70 mg/m2 was evaluated in 3 patients. The first patient
developed skin rash grade 2 during treatment cycle 2. During treatment
cycle 3 which was given at 60 mg/m2 the skin rash worsened to grade 3
(Fig. 1) which confirmed the need for an extended DLT observation
period as described above. Three additional patients were included at
this dose level. Although no formal DLTs were observed during treat-
ment cycle 1 in these patients, the gradual onset of drug-related skin
rash up to grade 2 during additional treatment cycles hampered timely
administration of CPC634 beyond treatment cycle 2. Therefore, the
60 mg/m2 dose level was expanded with an additional 3 patients. Of
these, one patient developed diarrhoea grade 3 during treatment cycle
1 due to colitis confirmed on endoscopy with biopsy and one patient
developed skin rash grade 3 during treatment cycle 3. It was concluded
from part 1, that 60 mg/m2 should be considered for further explora-
tion in part 3. Overall, skin rash was an important adverse event (AE)
with various presentation such as erythema, maculopapular, bullous
lesions affecting all parts of the body, localized rash near the injection
sites or PPE. After treatment cessation the skin rash recovered gradually
in the majority of the patients. Treatment of skin rash included cuta-
neous application of chlorhexidine 0,5%, clobetasol propionate 0,05%
or menthol 0,5% in cetomacrogol creme.
In part 2, 3 patients were enrolled at the 45 mg/m2. One patient
developed PPE grade 3 during treatment cycle 1. A second patient ex-
perienced a combination of hypomagnesemia grade 3 during treatment
cycle 1 and skin rash grade 3 during treatment cycle 2. Because 2 out of
3 patients enrolled in the first dose level of part 2 developed DLTs,
further dose exploration was not pursued.
In part 3, 6 patients received 60 mg/m2 CPC634 after dex-
amethasone premedication according to the schedule described. One
patient developed skin toxicity consisting of skin fissures and erythema
grade 4 during treatment cycle 5 which recovered after cessation of
treatment. Because the other 5 patients did not experience skin toxicity
that hampered repeated administrations, the RP2D for part 3 of the
study was determined at 60 mg/m2. Based on part 1 the MTD of
CPC634 was determined at 70 mg/m2 Q3W. An overview of all the dose
levels with the corresponding DLTs is summarized in Table 2.
Serious AEs observed in the study population were gastrointestinal
disorders (1 out of 9 related to CPC634), infection (1 out of 6 related to
CPC634), skin toxicities (5, all related to CPC634), neutropenia (2, both
related to CPC634), peripheral sensory neuropathy (1, related to
CPC634), pain (3, none related to CPC634), tumour bleeding (1, not
related to CPC634), pericardial tamponade (1, not related to CPC634),
hyperglycaemia (1, not related to CPC634), edema (1, related to
CPC634) and 1 case of death (related to progressive disease).
Adverse events related to CPC634 occurring in> 10% of patients
with the corresponding prevalence of grade ≥ 3 AE during therapy are
summarized in Table 3. Grade ≥ 3 AEs related to CPC634 were skin
toxicity (24%), neutropenia (6%), infection (6%), vertigo (3%), swollen
tongue (3%), increased aspartate aminotransferase (3%), increased
gamma-glutamyl transferase (3%), hypotension (3%) and hypomagne-
saemia (3%).
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3.3. Pharmacokinetics
Of the 24 patients enrolled in part 1, 22 patients contributed to
complete pharmacokinetic analysis for cycle 1. A summary of the
pharmacokinetic parameters of treatment cycle 1 is shown in Table 4.
There was a rank order increase in the AUCinf and Cmax with an increase
in dose for both released and total docetaxel.
Plasma concentration-time profile of released and total docetaxel at
60 mg/m2 are illustrated in Fig. 2A and B. The mean T½ of released
docetaxel ranged from 26.6 ± 10.9 h to 44.9 ± 9.9 h. The T½ of total
docetaxel across the cohorts varied from 29.9 ± 2.7 h to
41.0 ± 10.2 h. The Vd and CL were broadly consistent over the dose
range for both released and total docetaxel. The plasma AUCinf of re-
leased docetaxel levels did not differ between the patients who ex-
perienced DLT and those who did not (p= .1229, Fig. 2C). On the other
hand, the plasma AUCinf of total docetaxel was significantly higher in
patients experiencing a DLT (p = .0021, Fig. 2D).
3.4. Antitumour activity
Thirty patients (n = 21 in part 1, n = 3 in part 2, n = 6 in part 3)
were evaluable for tumour response. In part 1, 11 patients showed
stable disease and 1 patient had an unconfirmed partial response with a
duration of 77 days as best response. This patient had an adenocarci-
noma of unknown origin without any previous systemic therapy and
received CPC634 at 60 mg/m2. The total tumour burden measured in
this patient decreased from 129 mm at screening to 109 mm in cycle 2,
90 mm in cycle 4, 86 mm in cycle 6 and 85 mm at EOT. The median
duration of stable disease was 58 days (range, 27–482). One patient
received treatment up to 23 cycles (at 15 mg/m2). In part 2, all patients
showed progressive disease as best response. In part 3, five patients had
stable disease with a median duration of 125 days (range, 35–195). One
prostate cancer patient showed a 60% decrease in prostate-specific
antigen plasma concentration. This patient was not evaluable for
radiological response evaluation.
4. Discussion
Taxanes are frequently used in oncology but are known for their
narrow therapeutic index [2,4,15–17]. Taxanes are water-insoluble and
therefore have a relatively short circulation time and low tumour ex-
posure [2,4,15–17]. Nanotechnology can serve to improve target de-
livery of water-insoluble drugs while preserving healthy tissues.
CPC634 is such a novel nanomedicine and consists of docetaxel cova-
lently entrapped in a stabilized, 65 nm sized core-cross linked poly-
meric micelles (CCL-PMs). In this first in human study, the RP2D of
CPC634 was established at 60 mg/m2 administered Q3W with dex-
amethasone premedication. Other nanoparticles containing docetaxel
resulted in comparable RP2D's ranging between 60 and 75 mg/m2
[5,9,18]. The most important DLT of CPC634 observed in this study was
cumulative skin toxicity. We could demonstrate a pharmacokinetic/
toxicity relationship with higher plasma AUC for total docetaxel in
patients experiencing this DLT. Docetaxel is known to induce similar
skin toxicities [19,20]. Nanomedicines can induce the hypersensitivity
syndrome called C activation-related pseudoallergy (CARPA) which is
likely due to interaction with circulating serum proteins [21,22]. The
clinical manifestation of CARPA usually occurs during the first infusion
of the nanomedicine [21,22]. CPC634 is known to have a very low
protein affinity in human blood plasma [23] and the skin DLTs related
to CPC634 were observed after repeated administrations. We therefore
hypothesize that the mechanism of the skin DLTs is not due to CARPA
effect but rather related to the prolonged systemic exposure and dif-
ferent biodistribution of docetaxel released by CPC634. A head− to
head comparison of the systemic, intratumoural and skin pharmacoki-
netics of CPC634 with conventional docetaxel has been investigated in
the so-called CriTax study (Netherlands Trial Register number
NTR6474, www.trialregister.nl).). The published intratumoural phar-
macokinetic data showed that CPC634 resulted in a higher in-
tratumoural total docetaxel and comparable released docetaxel levels
relative to conventional docetaxel [13]. Although the RP2D of CPC634
is lower than that of conventional docetaxel, the increased in-
tratumoural exposure to docetaxel presumably compensates for that.
Thus, CPC634 has the potential to reduce the number of cycles needed
for clinical activity.
Neutropenia is a frequently occurring AE of conventional docetaxel.
The incidence of grade ≥ 3 neutropenia is approximately 50% with
Q3W docetaxel at 60–100 mg/m2[19,20]. In our study grade ≥ 3
neutropenia only occurred in two patients and only, short lasting, at the
highest dose level of 100 mg/m2. This is in contrast with other phase 1
studies with docetaxel-containing nanoparticles where neutropenia was
an important DLT [5,14,15]. In a pharmacodynamics analysis of con-
ventional docetaxel monotherapy, greater Cmax of unbound plasma
docetaxel was correlated with higher risk of grade 4 neutropenia [24].
Presumably, the unbound docetaxel reaches the bone marrow resulting
in neutropenia. Albumin and a1-acid glycoprotein are the main carriers
of docetaxel in the plasma [25]. The measured released docetaxel
Table 4
Summary of noncompartmental pharmacokinetic parameters of cycle 1, mean ± SD (% coefficient of variation) values by each dose level in part 1. Abbreviations;
Cmax, maximum concentration; Tmax, peak time; AUCinf, area under the curve from time 0 to infinity; T1/2 elimination half-life; CL, total clearance; Vz, volume of distribution.
Released docetaxel
Dose mg/m2 (N) Cmax (ng/ml) Tmax (hr) AUCinf (ng/h/ml) T½ (h) CL (liter/h/m2) Vz (liter/m2)
15 (3) 62.0 ± 13.5 (21.8) 2.5 ± 1.3 (50.8) 1214.2 ± 492.8 (40.6) 26.6 ± 10.9 (41.1) 13.6 ± 4.6 (34.0) 451.3 ± 121.2 (26.9)
30 (3) 67.4 ± 17.6 (26.1) 1.2 ± 0.3 (23.3) 3231.6 ± 2959.1 (91.6) 33.6 ± 1.4 (4.3) 14.7 ± 9.0 (61.3) 659.4 ± 339.4 (51.5)
60 (5) 217.3 ± 91.9 (41.6) 1.4 ± 0.4 (29.9) 4067.5 ± 2974.0 (24.8) 39.7 ± 9.4 (23.6) 15.3 ± 3.6 (23.6) 737.5 ± 201.0 (27.3)
70 (6) 341.0 ± 170.0 (49.8) 1.8 ± 1.2 (67.0) 6213.1 ± 1938.9 (31.2) 41.0 ± 2.9 (7.0) 12.3 ± 3.9 (31.6) 647.3 ± 170.4 (26.3)
80 (2) 325.5 ± 20.9 (6.4) 1.5 ± 0.7 (47.1) 5479.0 ± 424.0 (7.7) 39.60 ± 0.05 (0.1) 14.6 ± 1.2 (8.4) 685.1 ± 57.1 (8.3)
100 (3) 321.9 ± 120.6 (37.5) 1.8 ± 0.3 (15.7) 8424.4 ± 562.5 (6.7) 44.9 ± 9.9 (22.1) 12.0 ± 0.7 (5.6) 690.9 ± 176.2 (25.5)
Total docetaxel
Dose mg/m2 (N) Cmax (ng/ml) Tmax (hr) AUCinf (ng/h/ml) T½ (h) CL (liter/h/m2) Vz (liter/m2)
15 (3) 7793.8 ± 1106.7 (14.2) 1.8 ± 0.3 (15.5) 309,676.9 ± 22,012.7 (7.1) 33.2 ± 2.6 (7.8) 0.05 ± 0.00 (6.0) 2.2 ± 0.1 (3.6)
30 (3) 17,729.6 ± 3407.0 (19.2) 1.6 ± 0.6 (33.9) 514,212.9 ± 167,829.0 (32.6) 29.9 ± 2.7 (9.2) 0.06 ± 0.02 (31.0) 2.5 ± 0.5 (21.8)
60 (5) 27,144.4 ± 7999.3 (29.5) 1.5 ± 0.4 (23.5) 973,986.6 ± 246,491.0 (25.3) 31.6 ± 1.3 (4.2) 0.06 ± 0.02 (26.3) 2.9 ± 0.8 (28.2)
70 (6) 29,711.8 ± 13,361.5 (45.0) 2.6 ± 1.5 (60.2) 1,179,287.4 ± 500,045.7 (42.4) 32.9 ± 3.6 (11.0) 0.07 ± 0.02 (33.5) 3.2 ± 1.2 (37.5)
80 (2) 28,685.4 ± 5327.1 (18.6) 1.3 ± 0.4 (28.3) 1,116,310.7 ± 119,844.0 (10.7) 41.1 ± 10.2 (24.9) 0.07 ± 0.01 (9.9) 4.1 ± 10.2 (17.5)
100 (3) 44,116.1 ± 8645.3 (19.6) 3.3 ± 2.3 (67.9) 1,836,280.0 ± 385,084.5 (21.0) 35.0 ± 3.2 (9.2) 0.06 ± 0.01 (23.0) 2.7 ± 0.8 (28.7)
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concentration in this study includes both protein bound and unbound
docetaxel. A plausible explanation for the low incidence of neutropenia
in this study could be the lower Cmax of released docetaxel from CPC634
compared to conventional docetaxel and other docetaxel-containing
nanoparticles [1,21]. The CCL-PMs in CPC634 enable a stable and slow
release of docetaxel from the nanoparticles that could explain this low
Cmax. The pharmacokinetic profile of CPC634 compared to published
data of conventional docetaxel (100 mg/m2 dose as a comparison)
demonstrate a 7 fold lower Cmax, 2 fold longer half-life and comparable
CL and AUC for released docetaxel, whereas in our aforementioned
CriTax study [13] CPC634 has a lower Cmax of released docetaxel
compared to conventional docetaxel. The 309 fold higher AUC of total
docetaxel in combination with 2 fold longer half-life and 283 fold lower
CL indicate a high retention of docetaxel in the nanoparticles which
supports a prolonged systemic exposure to docetaxel [1,19]. A PET
imaging of the intratumoural docetaxel exposure by CPC634 is studied
in the PICCOLO trial (Clinicaltrials.gov number NCT03712423).
Conventional docetaxel is often administered as a part of combi-
national chemotherapeutic regimens which all have a high risk of de-
veloping febrile neutropenia [20]. Using CPC634 instead of conven-
tional docetaxel in any of these regimens could have the potential to
reduce this AE. Further studies are therefore indicated to explore safety
and efficacy of CPC634 as monotherapy and in combination with any of
these regimens.
In conclusion this phase 1 study has demonstrated that Q3W ad-
ministration of CPC634 at 60 mg/m2 is feasible with manageable
toxicity and a small risk of neutropenia. The pharmacokinetic profile of
CPC634 is dose-proportional with prolonged systemic exposure to
docetaxel in accordance with preclinical data. A phase II efficacy study
(the CINOVA trial) of CPC634 monotherapy is ongoing (Clinicaltrials.
gov number NCT03742713).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2020.06.020.
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